Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Oct 28;16(10):e0258949.
doi: 10.1371/journal.pone.0258949. eCollection 2021.

Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function

Anna Jonsson Holmdahl  1 , Helena Norberg  2 , Fredrik Valham  1 , Ellinor Bergdahl  1 , Krister Lindmark  1
Affiliations
Observational Study

Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function

Anna Jonsson Holmdahl et al. PLoS One. .

Abstract

Aims: Impaired renal function is a major contributor to the low proportion of mineralocorticoid receptor antagonist (MRA) treatment in patients with heart failure with reduced ejection fraction (HFrEF). Our aims were to investigate the impact of MRA treatment on all-cause mortality and worsening renal function (WRF) in patients with HFrEF and moderately impaired renal function.

Methods: Retrospective data between 2010-2018 on HFrEF patients from a single-centre hospital with estimated glomerular renal function (eGFR) < 60 ml/min/1.73 m2 were analysed. WRF was defined as a decline of by eGFR ≥ 20%.

Results: 416 patients were included, 131 patients on MRA and 285 without MRA, mean age was 77 years (SD ± 9) and 82 years (SD ± 9), respectively. Median follow-up was 2 years. 128 patients (32%) experienced WRF, 25% in the MRA group and 30% in patients without MRA (p = 0.293). In multivariable analysis, hospitalization for heart failure and systolic blood pressure were associated with WRF (p = 0.015 and p = <0.001), but not use of MRA (p = 0.421). MRA treatment had no impact on the risk of adjusted all-cause mortality (HR 0.93; 95% CI, 0.66-1.32 p = 0.685). WRF was associated with increased adjusted risk of all-cause mortality (HR 1.43; 95% CI, 1.07-1.89 p = 0.014). Use of MRA did not increase the adjusted overall risk of mortality even when experiencing WRF (HR 1.15; 95% CI, 0.81-1.63 p = 0.422).

Conclusion: In this cohort of elderly HFrEF patients with moderately impaired renal function, MRA did not increase risk for WRF or all-cause mortality.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Patient selection flow chart.
Fig 2
Fig 2
A) Frequency of worsening renal function (WRF) stratified into follow-up time. B) Change in eGFR between index and follow-up.
Fig 3
Fig 3. Kaplan-Meier survival plot for On MRA versus No MRA.
Log rank p<0.001.
See this image and copyright information in PMC

References

    1. Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al.. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018;72(4):351–66. doi: 10.1016/j.jacc.2018.04.070 - DOI - PubMed
    1. Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstrom U, et al.. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2018;20(9):1326–34. doi: 10.1002/ejhf.1182 - DOI - PubMed
    1. Clark H, Krum H, Hopper I. Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. European journal of heart failure. 2014;16(1):41–8. doi: 10.1002/ejhf.13 - DOI - PubMed
    1. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, et al.. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008;10(2):188–95. doi: 10.1016/j.ejheart.2008.01.011 - DOI - PubMed
    1. Damman K, Jaarsma T, Voors AA, Navis G, Hillege HL, van Veldhuisen DJ. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). European journal of heart failure. 2009;11(9):847–54. doi: 10.1093/eurjhf/hfp108 - DOI - PubMed

Publication types

MeSH terms

Substances